drugset / Trial / NCT05815186
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
NaSingle-groupOpen-labelTreatment
Summary
Study record has been combined with NCT05815173. See NCT05815173 for summary.
Timeline
- Start
- 2024-04
- Primary completion
- 2025-04
- Completion
- 2026-04
Outcome
Outcome not reported
Stopped: “Study record has been combined with NCT05815173 (Phase I/II study).”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ladarixin | Unknown | — | — |
| Subject | Sotorasib | Small molecule | 960 mg | Oral |